SREB3 Inhibitors
SREB3 inhibitors are a class of chemical compounds that specifically target and inhibit the activity of SREB3 (Sterol Regulatory Element-Binding Protein 3), a transcription factor involved in the regulation of lipid metabolism and cholesterol homeostasis. SREB3 belongs to the SREBP family of proteins, which are key regulators of genes that control the synthesis and uptake of cholesterol, fatty acids, and triglycerides. SREB3 is localized in the endoplasmic reticulum (ER) membrane and is activated through a proteolytic process that releases its N-terminal domain, allowing it to enter the nucleus and bind to sterol regulatory elements (SREs) in the promoter regions of target genes. By controlling the expression of these genes, SREB3 plays a critical role in maintaining lipid balance within cells. Inhibitors of SREB3 interfere with its ability to regulate these genes, potentially leading to disruptions in lipid metabolism and cellular homeostasis.
The mechanism of action of SREB3 inhibitors typically involves binding to specific domains of the protein that are crucial for its activation, transport, or DNA-binding capacity. Some inhibitors may prevent the cleavage and activation of SREB3 by interfering with the proteolytic machinery, while others may block its ability to translocate to the nucleus or bind to DNA. By inhibiting SREB3, these compounds disrupt the transcriptional regulation of genes involved in lipid synthesis, transport, and storage, leading to changes in cellular lipid profiles. Research into SREB3 inhibitors provides valuable insights into the molecular pathways that regulate lipid metabolism and the role of transcription factors in maintaining metabolic homeostasis. Understanding how SREB3 controls lipid-related gene expression also highlights its importance in broader metabolic processes, such as energy production, membrane synthesis, and intracellular signaling, all of which rely on the proper regulation of lipid availability.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin may elevate intracellular cAMP, which could lead to enhanced protein kinase A (PKA) activity. PKA activation can alter transcription factor activity, potentially resulting in the downregulation of SREB3 gene expression due to changes in transcriptional dynamics. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
Rolipram's inhibition of phosphodiesterase-4 (PDE4) leads to increased cAMP levels, which can culminate in a decrease of SREB3 expression through PKA-dependent transcriptional control mechanisms that govern GPCR gene expression. | ||||||
(±)-JQ1 | 1268524-69-1 | sc-472932 sc-472932A | 5 mg 25 mg | $231.00 $863.00 | 1 | |
By binding competitively to the acetyl-lysine recognition pockets of BET bromodomain proteins, JQ1 can disrupt the recruitment of transcriptional machinery required for the expression of certain genes, potentially leading to a reduced expression of SREB3. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG-132 halts the proteasomal degradation of ubiquitinated proteins, which might trigger a cellular stress response, and this response could include the attenuation of SREB3 expression as part of a broader shift in cellular protein homeostasis. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A, by inhibiting histone deacetylases (HDACs), causes an increase in acetylated histones, which may lead to a more open chromatin state. However, this alteration can also repress transcription of certain genes, potentially reducing SREB3 transcription as part of a wider change in gene expression patterns. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
5-Azacytidine can induce DNA demethylation, which may disrupt gene expression patterns. This drug could potentially lead to a decrease in SREB3 expression by altering the methylation status of the gene's promoter region, thus suppressing its transcription. | ||||||
Curcumin | 458-37-7 | sc-200509 sc-200509A sc-200509B sc-200509C sc-200509D sc-200509F sc-200509E | 1 g 5 g 25 g 100 g 250 g 1 kg 2.5 kg | $37.00 $69.00 $109.00 $218.00 $239.00 $879.00 $1968.00 | 47 | |
Curcumin has been shown to have a suppressive effect on the transcription of various genes. It could decrease SREB3 expression by interacting with transcriptional machinery or signaling pathways that control GPCR gene transcription. | ||||||
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $66.00 $325.00 $587.00 $1018.00 | 28 | |
Retinoic acid, through its interaction with retinoic acid receptors, can initiate a transcriptional response that decreases the expression of certain genes, potentially including SREB3, by altering gene transcription networks. | ||||||
Wnt-C59 | 1243243-89-1 | sc-475634 sc-475634A sc-475634B | 5 mg 10 mg 50 mg | $214.00 $326.00 $1275.00 | 1 | |
Wnt-C59 inhibits the production of Wnt lipid modifications, which are necessary for Wnt signaling. By inhibiting this pathway, C59 could decrease SREB3 expression as part of a broader suppression of Wnt target genes. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD 98059 selectively inhibits MEK1/2, enzymes in the MAPK/ERK pathway. This inhibition can lead to a decrease in the expression of genes that are controlled by this pathway, including potentially SREB3. | ||||||